{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:05:42Z","timestamp":1781269542352,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s13318-024-00926-z","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T12:47:35Z","timestamp":1733748455000},"page":"65-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics of Zilurgisertib With and Without Food from Single and Multiple Ascending Dose Phase 1 Studies in Healthy Adults"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4869-9492","authenticated-orcid":false,"given":"Yan-ou","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3437-4399","authenticated-orcid":false,"given":"Xiaohua","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Getsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0400-514X","authenticated-orcid":false,"given":"Phillip","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Rockich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"issue":"7","key":"926_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/biomedicines9070736","volume":"9","author":"T Katagiri","year":"2021","unstructured":"Katagiri T, Tsukamoto S, Kuratani M. Accumulated knowledge of activin receptor-like kinase 2 (ALK2)\/activin A receptor, type 1 (ACVR1) as a target for human disorders. Biomedicines. 2021;9(7):736. https:\/\/doi.org\/10.3390\/biomedicines9070736.","journal-title":"Biomedicines."},{"issue":"32","key":"926_CR2","doi-asserted-by":"publisher","first-page":"20729","DOI":"10.1021\/acsomega.1c02983","volume":"6","author":"L Rooney","year":"2021","unstructured":"Rooney L, Jones C. Recent advances in ALK2 inhibitors. ACS Omega. 2021;6(32):20729\u201334. https:\/\/doi.org\/10.1021\/acsomega.1c02983.","journal-title":"ACS Omega"},{"issue":"4","key":"926_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/biom10040519","volume":"10","author":"OE Olsen","year":"2020","unstructured":"Olsen OE, Hella H, Elsaadi S, et al. Activins as dual specificity TGF-\u03b2 family molecules: SMAD-activation via activin- and BMP-type 1 receptors. Biomolecules. 2020;10(4):519. https:\/\/doi.org\/10.3390\/biom10040519.","journal-title":"Biomolecules"},{"key":"926_CR4","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.54582","volume":"9","author":"S Aykul","year":"2020","unstructured":"Aykul S, Corpina RA, Goebel EJ, et al. Activin A forms a non-signaling complex with ACVR1 and type II activin\/BMP receptors via its finger 2 tip loop. Elife. 2020;9: e54582. https:\/\/doi.org\/10.7554\/eLife.54582.","journal-title":"Elife"},{"issue":"303","key":"926_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1126\/scitranslmed.aac4358","volume":"7","author":"SJ Hatsell","year":"2015","unstructured":"Hatsell SJ, Idone V, Wolken DM, et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015;7(303):303\u2013137. https:\/\/doi.org\/10.1126\/scitranslmed.aac4358.","journal-title":"Sci Transl Med."},{"issue":"50","key":"926_CR6","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1073\/pnas.1510540112","volume":"112","author":"K Hino","year":"2015","unstructured":"Hino K, Ikeya M, Horigome K, et al. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci U S A. 2015;112(50):15438\u201343. https:\/\/doi.org\/10.1073\/pnas.1510540112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"926_CR7","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1182\/blood-2010-10-313064","volume":"117","author":"AU Steinbicker","year":"2011","unstructured":"Steinbicker AU, Sachidanandan C, Vonner AJ, et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood. 2011;117(18):4915\u201323. https:\/\/doi.org\/10.1182\/blood-2010-10-313064.","journal-title":"Blood"},{"issue":"1","key":"926_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","volume":"133","author":"G Weiss","year":"2019","unstructured":"Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40\u201350. https:\/\/doi.org\/10.1182\/blood-2018-06-856500.","journal-title":"Blood"},{"issue":"4","key":"926_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.ajkd.2009.12.030","volume":"55","author":"JL Babitt","year":"2010","unstructured":"Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis. 2010;55(4):726\u201341. https:\/\/doi.org\/10.1053\/j.ajkd.2009.12.030.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"926_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000452104","volume":"26","author":"AJ Madu","year":"2017","unstructured":"Madu AJ, Ughasoro MD. Anaemia of chronic disease: an in-depth review. Med Princ Pract. 2017;26(1):1\u20139. https:\/\/doi.org\/10.1159\/000452104.","journal-title":"Med Princ Pract"},{"issue":"13","key":"926_CR11","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","volume":"129","author":"M Asshoff","year":"2017","unstructured":"Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129(13):1823\u201330. https:\/\/doi.org\/10.1182\/blood-2016-09-740092.","journal-title":"Blood"},{"key":"926_CR12","doi-asserted-by":"publisher","unstructured":"Liljesthr\u00f6m M, Pignolo R, Kaplan F. Epidemiology of the global fibrodysplasia ossificans progressiva (FOP) community. J Rare Dis Res Treat 2020;5(2):31\u20136. https:\/\/doi.org\/10.29245\/2572-9411\/2020\/2.1196","DOI":"10.29245\/2572-9411\/2020\/2.1196"},{"key":"926_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-021-01983-2","volume":"16","author":"RJ Pignolo","year":"2021","unstructured":"Pignolo RJ, Hsiao EC, Baujat G, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021;16:350. https:\/\/doi.org\/10.1186\/s13023-021-01983-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"926_CR14","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1038\/s41467-022-33956-9","volume":"13","author":"Y-S Yang","year":"2022","unstructured":"Yang Y-S, Kim J-M, Xie J, et al. Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery. Nat Comm. 2022;13(1):6175. https:\/\/doi.org\/10.1038\/s41467-022-33956-9.","journal-title":"Nat Comm"},{"issue":"1","key":"926_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/biom14010101","volume":"14","author":"D Srinivasan","year":"2024","unstructured":"Srinivasan D, Arostegui M, Goebel EJ, et al. How activin A became a therapeutic target in fibrodysplasia ossificans progressiva. Biomolecules. 2024;14(1):101. https:\/\/doi.org\/10.3390\/biom14010101.","journal-title":"Biomolecules"},{"issue":"5","key":"926_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000365770","volume":"5","author":"I H\u00fcning","year":"2014","unstructured":"H\u00fcning I, Gillessen-Kaesbach G. Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation. Mol Syndromol. 2014;5(5):201\u201311. https:\/\/doi.org\/10.1159\/000365770.","journal-title":"Mol Syndromol."},{"issue":"3","key":"926_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/humu.20868","volume":"30","author":"FS Kaplan","year":"2009","unstructured":"Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30(3):379\u201390. https:\/\/doi.org\/10.1002\/humu.20868.","journal-title":"Hum Mutat"},{"issue":"5","key":"926_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525\u20137. https:\/\/doi.org\/10.1038\/ng1783.","journal-title":"Nat Genet"},{"issue":"5","key":"926_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ng.2925","volume":"46","author":"KR Taylor","year":"2014","unstructured":"Taylor KR, Mackay A, Truffaux N, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014;46(5):457\u201361. https:\/\/doi.org\/10.1038\/ng.2925.","journal-title":"Nat Genet"},{"issue":"4","key":"926_CR20","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.3892\/mmr.2019.10556","volume":"20","author":"F Shi","year":"2019","unstructured":"Shi F, Gao J, Zou J, et al. Targeting heterotopic ossification by inhibiting activin receptor-like kinase 2 function (review). Mol Med Rep. 2019;20(4):2979\u201389. https:\/\/doi.org\/10.3892\/mmr.2019.10556.","journal-title":"Mol Med Rep"},{"issue":"3","key":"926_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.2728","volume":"31","author":"RJ Pignolo","year":"2016","unstructured":"Pignolo RJ, Bedford-Gay C, Liljesthr\u00f6m M, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31(3):650\u20136. https:\/\/doi.org\/10.1002\/jbmr.2728.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"926_CR22","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/bcp.13777","volume":"85","author":"EC Hsiao","year":"2019","unstructured":"Hsiao EC, Di Rocco M, Cali A, et al. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br J Clin Pharmacol. 2019;85(6):1199\u2013207. https:\/\/doi.org\/10.1111\/bcp.13777.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"926_CR23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42614","volume":"15","author":"U Shaikh","year":"2023","unstructured":"Shaikh U, Khan A, Kumari P, et al. Novel therapeutic targets for fibrodysplasia ossificans progressiva: emerging strategies and future directions. Cureus. 2023;15(7): e42614. https:\/\/doi.org\/10.7759\/cureus.42614.","journal-title":"Cureus."},{"issue":"12","key":"926_CR24","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3390\/genes14122162","volume":"14","author":"S Anwar","year":"2023","unstructured":"Anwar S, Yokota T. Navigating the complex landscape of fibrodysplasia ossificans progressiva: from current paradigms to therapeutic frontiers. Genes (Basel). 2023;14(12):2162. https:\/\/doi.org\/10.3390\/genes14122162.","journal-title":"Genes (Basel)."},{"issue":"suppl 1","key":"926_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2020-136138","volume":"136","author":"Y Chen","year":"2020","unstructured":"Chen Y, Stubbs MC, Pusey M, et al. Characterization of INCB00928, a potent and selective ALK2 inhibitor for the treatment of anemia. Blood. 2020;136(suppl 1):52. https:\/\/doi.org\/10.1182\/blood-2020-136138.","journal-title":"Blood"},{"issue":"8","key":"926_CR26","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1021\/mp300250r","volume":"9","author":"N Idkaidek","year":"2012","unstructured":"Idkaidek N, Arafat T. Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. Mol Pharm. 2012;9(8):2358\u201363. https:\/\/doi.org\/10.1021\/mp300250r.","journal-title":"Mol Pharm"},{"issue":"5","key":"926_CR27","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jsps.2016.10.002","volume":"25","author":"NM Idkaidek","year":"2017","unstructured":"Idkaidek NM. Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans. Saudi Pharm J. 2017;25(5):671\u20135. https:\/\/doi.org\/10.1016\/j.jsps.2016.10.002.","journal-title":"Saudi Pharm J."},{"issue":"7","key":"926_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4155\/bio-2022-0016","volume":"14","author":"Z Xun","year":"2022","unstructured":"Xun Z, Yuska B, Wang P, et al. Bioanalysis of INCB000928 in human saliva: nonspecific binding and inhomogeneous concentration. Bioanalysis. 2022;14(7):405\u201319. https:\/\/doi.org\/10.4155\/bio-2022-0016.","journal-title":"Bioanalysis"},{"issue":"5","key":"926_CR29","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1542\/peds.2005-0469","volume":"116","author":"JA Kitterman","year":"2005","unstructured":"Kitterman JA, Kantanie S, Rocke DM, et al. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics. 2005;116(5):e654\u201361. https:\/\/doi.org\/10.1542\/peds.2005-0469.","journal-title":"Pediatrics"},{"issue":"12","key":"926_CR30","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jcph.1484","volume":"59","author":"AM Barbour","year":"2019","unstructured":"Barbour AM, Punwani N, Epstein N, et al. Effect of itraconazole or rifampin on itacitinib pharmacokinetics when administered orally in healthy subjects. J Clin Pharmacol. 2019;59(12):1641\u20137. https:\/\/doi.org\/10.1002\/jcph.1484.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"926_CR31","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00228-021-03184-z","volume":"77","author":"T Ji","year":"2021","unstructured":"Ji T, Rockich K, Epstein N, et al. Evaluation of drug\u2013drug interactions of pemigatinib in healthy participants. Eur J Clin Pharmacol. 2021;77(12):1887\u201397. https:\/\/doi.org\/10.1007\/s00228-021-03184-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"926_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0091270003252243","volume":"43","author":"C Bu\u00f6en","year":"2003","unstructured":"Bu\u00f6en C, Holm S, Thomsen MS. Evaluation of the cohort size in phase I dose escalation trials based on laboratory data. J Clin Pharmacol. 2003;43(5):470\u20136. https:\/\/doi.org\/10.1177\/0091270003252243.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"926_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/cts.12582","volume":"12","author":"J Shen","year":"2019","unstructured":"Shen J, Swift B, Mamelok R, et al. Design and conduct considerations for first-in-human trials. Clin Transl Sci. 2019;12(1):6\u201319. https:\/\/doi.org\/10.1111\/cts.12582.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"926_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40268-016-0170-8","volume":"17","author":"N Idkaidek","year":"2017","unstructured":"Idkaidek N, Arafat T, Hamadi H, et al. Saliva versus plasma bioequivalence of azithromycin in humans: validation of class I drugs of the salivary excretion classification system. Drugs R D. 2017;17(1):219\u201324. https:\/\/doi.org\/10.1007\/s40268-016-0170-8.","journal-title":"Drugs R D."},{"issue":"1","key":"926_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/ftd.0000000000000462","volume":"40","author":"SHJ van den Elsen","year":"2018","unstructured":"van den Elsen SHJ, Oostenbrink LM, Heysell SK, et al. Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring. Ther Drug Monit. 2018;40(1):17\u201337. https:\/\/doi.org\/10.1097\/ftd.0000000000000462.","journal-title":"Ther Drug Monit"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00926-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00926-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00926-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T06:49:00Z","timestamp":1738824540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00926-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00926-z","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"30 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yan-ou Yang, Xiaohua Gong, Jay Getsy, Phillip Wang, Xiang Liu, Jennifer Sheng, Xuejun Chen, and Kevin Rockich are employees of and have stock ownership in Incyte Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Studies were performed in accordance with ethical principles based on the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards, International Council for Harmonisation Guideline for Good Clinical Practice, and applicable laws and regulations. The study protocols and the ethical, scientific, and medical appropriateness of the study were approved by the institutional review board (Advarra Inc, Columbia, MD, USA) before study initiation (00928-101, approval number: CA29227, approved October 16, 2019; 00928-102, approval number CA31709, approved August 4, 2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}